drugset / Trial / NCT00508742

Study Evaluating the Impact of a 13-valent Pneumococcal Conjugate Vaccine on Nasopharyngeal Colonization

NCT00508742

Phase 3 Completed 1866 enrolled Pfizer
RandomizedParallel-groupQuadruple-blindPrevention

Summary

This study is designed to assess the impact of 13-valent Pneumococcal Conjugate Vaccine (13vPnC) on nasopharyngeal colonization with Streptococcus pneumoniae in healthy infants.

Timeline

Start
2007-12
Primary completion
2011-08
Completion
2011-08

Publications

Drugs

EvaluationDrugModalityDoseRoute
Comparator Prevnar 13 Vaccine